News

Imetelstat Nearly Doubles Survival in High-Risk Myelofibrosis

Treatment /

An updated analysis showed that the telomerase inhibitor Imetelstat significantly improves survival in patients with high-risk myelofibrosis whose disease relapsed or became resistant after JAK inhibitor treatment. Researchers compared 59 IMbark patients with a matched real-world group of 54 patients treated before 2016. After nearly four years of follow-up, median overall survival reached 30.7 months […]

Imetelstat Nearly Doubles Survival in High-Risk Myelofibrosis Read More »

FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer

Drug Approvals /

The FDA has approved Datroway (datopotamab deruxtecan-dlnk, Dato-DXd) for adults with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval is based on results from the phase 3 TROPION-Breast02 trial. Dato-DXd significantly improved outcomes compared with standard chemotherapy. Median overall survival reached 23.7 months versus 18.7 months

FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer Read More »

GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in Large Real-World Study

Research Advances /

A real-world study suggests that GLP-1 receptor agonists, including semaglutide, may significantly reduce the risk of cancer metastasis in patients with early-stage solid tumors. Researchers analyzed data from over 10,000 patients with stage I–III cancers and compared those taking GLP-1 drugs with matched patients using DPP-4 inhibitors. Results showed a 31% to 50% reduction in

GLP-1 Drugs Linked to Lower Cancer Metastasis Risk in Large Real-World Study Read More »

Breakthrough Advances in Targeted Therapy Reshape Lung Cancer Treatment Landscape

Targeted Therapy /

New studies highlight major progress in non-small cell lung cancer (NSCLC) treatment, particularly with targeted therapies and antibody-drug conjugates. The combination of amivantamab and lazertinib achieved a median overall survival of 41 months in treatment-naive patients with atypical EGFR-mutated NSCLC. Pumitamig, a bispecific antibody targeting PD-L1 and VEGF-A, showed a 70% response rate and 100%

Breakthrough Advances in Targeted Therapy Reshape Lung Cancer Treatment Landscape Read More »

Biomarker-Guided HER2/CD47 Therapy Shows Durable Responses After Enhertu Failure

Clinical Trails /

A phase 1b/2 trial showed promising results for a new combination therapy in patients with HER2-positive metastatic breast cancer who had already failed treatment with Enhertu. The study evaluated zanidatamab-hrii, a HER2-targeted bispecific antibody, together with evorpacept, a CD47 blocker, in 24 heavily pretreated patients. Overall, the response rate was 33.3%, but patients with centrally

Biomarker-Guided HER2/CD47 Therapy Shows Durable Responses After Enhertu Failure Read More »

mRNA-Lipid Nanoparticle Cancer Therapies Show Promise in Early Clinical Development

Research Advances /

mRNA-based cancer therapies work by delivering genetic instructions that tell cells to produce specific proteins without changing DNA, reducing risks linked to genome integration. However, mRNA is unstable and difficult to deliver into cells because it degrades quickly and cannot easily cross cell membranes. To overcome this, scientists use lipid nanoparticles (LNPs) that protect mRNA

mRNA-Lipid Nanoparticle Cancer Therapies Show Promise in Early Clinical Development Read More »

Adjuvant Pembrolizumab Reduces Recurrence and Mortality Risk in High-Risk Clear Cell Renal Cell Carcinoma After Surgery

Treatment /

A roundtable discussion led by Thomas Hutson highlighted the growing role of adjuvant Pembrolizumab in high-risk clear cell renal cell carcinoma (ccRCC) following nephrectomy, based on results from the phase 3 KEYNOTE-564 trial. The study compared one year of pembrolizumab versus placebo in patients with resected high-risk disease and showed a 29% reduction in recurrence

Adjuvant Pembrolizumab Reduces Recurrence and Mortality Risk in High-Risk Clear Cell Renal Cell Carcinoma After Surgery Read More »

Ibrutinib Delivers 10-Year Survival Benefit and Durable Disease Control in High-Risk CLL

Treatment /

Ten-year follow-up data from the phase 2 NCT01500733 trial showed that continuous treatment with Ibrutinib provides long-term disease control for patients with high-risk chronic lymphocytic leukemia (CLL), including those with TP53 abnormalities. Among 84 patients, median progression-free survival reached 7.2 years, while median overall survival was not yet reached. The 10-year progression-free survival rate was

Ibrutinib Delivers 10-Year Survival Benefit and Durable Disease Control in High-Risk CLL Read More »

Nadunolimab Combination Shows Early Complete Remissions in High-Risk MDS

Clinical Trails /

An ongoing phase 1b/2a clinical trial is showing encouraging early results for Nadunolimab combined with azacitidine in patients with high-risk myelodysplastic syndrome (MDS), and with azacitidine plus Venetoclax in relapsed or refractory acute myeloid leukemia (AML). The investigator-initiated study, conducted at MD Anderson Cancer Center, has completed its phase 1b dose-escalation stage without any dose-limiting

Nadunolimab Combination Shows Early Complete Remissions in High-Risk MDS Read More »

Lutetium Lu 177 vipivotide tetraxetan Improves PSA Responses in Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 Trial

Treatment /

The phase 3 PSMAddition trial showed that adding Lutetium Lu 177 vipivotide tetraxetan to standard androgen-deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) significantly improved prostate-specific antigen (PSA) responses in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The study included 1,144 patients, most with high tumor burden and bone metastases. Researchers previously

Lutetium Lu 177 vipivotide tetraxetan Improves PSA Responses in Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 Trial Read More »